Gummy Supplement Label Architecture: How to Build Every Panel for FDA Compliance

Why Gummy Label Compliance Is More Complex Than Capsule or Tablet Products

Most supplement label compliance guidance was written with capsules, tablets, and softgels in mind. Gummy products introduce a set of formulation and manufacturing variables that these frameworks do not account for — and FDA investigators are increasingly aware of that gap. When an investigator pulls a label off a gummy product and cross-references it against batch records, they are looking for consistency between the label claim and the delivered dose. For gummies, that consistency is harder to achieve and easier to lose.

Moisture loss is the most common driver of gummy label non-compliance. When a gummy loses water during drying, coating, or shelf aging, the physical unit shrinks — but the active ingredient concentration does not disappear. Depending on how the formula is built and how the label claim is calculated, moisture loss can push a gummy above or below its stated potency per serving. If your label says each gummy delivers 10 mg of zinc and your product consistently delivers 13 mg because the batch dried down more than expected, that is a label accuracy issue FDA will cite. If it delivers 7 mg, you have a potency failure. Neither outcome is acceptable under 21 CFR Part 111.

Beyond potency, gummy manufacturers must navigate serving size declaration, net quantity of contents, ingredient listing order, allergen disclosure, and structure/function claim substantiation — all of which are governed by overlapping FDA regulations that apply to both dietary supplements and food products. Gummies occupy a regulatory space that draws from both frameworks, and that dual standard is exactly where most label errors are made.

The Supplement Facts Panel: Line-by-Line Requirements for Gummy Products

The Supplement Facts panel is the most regulated section of your label and the first place FDA will look during an inspection or review. For gummy manufacturers, several elements of this panel carry gummy-specific compliance risk that generic label guidance does not address.

Serving Size and Serving Size Basis

Your serving size must be declared in a consumer-meaningful unit — typically the number of gummies — and must reflect the amount that delivers the nutrients listed in the panel. This sounds straightforward, but gummy manufacturers frequently run into problems when serving size is set during formula development and the deposited unit weight drifts during commercial production. If your label declares a serving size of two gummies delivering 500 mg of vitamin C, and your production line consistently deposits gummies that are 10 percent lighter than the development target, you are no longer delivering the stated dose at the declared serving size. Your process validation and in-process weight checks must lock the unit weight to the serving size assumption baked into the label.

Nutrient Declarations and Overage Calculations

FDA requires that nutrient values on the Supplement Facts panel be accurate to within allowable variability. For vitamins and minerals, the finished product must contain at least 100 percent of the declared value through the end of shelf life. Gummy manufacturers routinely build in overages to account for cooking losses, moisture-related concentration shifts, and ingredient degradation during shelf life. The problem arises when overages are calculated incorrectly — either too low, resulting in out-of-specification potency at end of shelf life, or too high, resulting in label inaccuracy at time of manufacture.

Your overage strategy must be documented, justified by stability data, and reflected accurately in your master manufacturing record. If your label claims are based on overage-adjusted formula targets, your QC release specifications must confirm that finished product potency falls within the range that supports the label claim at both time of manufacture and end of shelf life.

Ingredient Listing in the Other Ingredients Deck

Below the Supplement Facts panel, gummy products typically carry a long list of other ingredients — gelatin or pectin, glucose syrup, sugar, citric acid, natural flavors, colorants, carnauba wax, and coating agents. These must be listed in descending order of predominance by weight as they are added to the product, per 21 CFR Part 101. Gelatin or pectin is almost always the first or second ingredient by weight and must be listed accurately. If your formula uses a blend of gelatin and pectin — a common approach in hybrid gummy systems — both must appear. If you transition from a gelatin base to a pectin base for a vegan reformulation, the label must be updated before the reformulated product ships. Releasing reformulated product under the old label is a labeling violation.

Colorants require specific attention. Certified color additives such as FD&C Red 40 must be declared by their full name. Colors exempt from certification, such as annatto or turmeric extract, can be declared as "color added" or by name. Using the wrong declaration for a color additive — or omitting it entirely — creates both a labeling violation and a potential adulteration issue.

Front Panel and Principal Display Panel Requirements

The principal display panel (PDP) is the portion of the label most likely to be seen by a consumer at point of sale. For gummy supplements, the PDP must carry the statement of identity, the net quantity of contents, and any characterizing claims that drive purchase decisions. Each of these elements is governed by specific FDA requirements, and gummy manufacturers frequently miscalculate or misformat at least one of them.

Statement of Identity

Your product must be identified as a "dietary supplement" on the PDP. Many gummy brands use the word "gummies" prominently on the front panel without clearly calling the product a dietary supplement. FDA has cited this in warning letters when the overall label presentation could cause consumers to mistake a supplement for a food or candy. The statement of identity should appear in a type size that is prominent and conspicuous relative to the other text on the PDP.

Net Quantity of Contents

Net quantity must be declared by count for gummy products — for example, "60 gummies" — and must appear on the PDP in a type size that meets FDA minimum requirements based on the principal display panel area. The count declared must match what is actually in the container. If your fill target is 60 gummies but your depositing line runs with unit weight variability that occasionally results in 58 or 59 gummies per bottle, your label count is inaccurate. Net quantity compliance requires that your fill process, unit weight controls, and count verification procedures all be calibrated to consistently deliver what the label states. Under-fills are a labeling violation. They are also the type of consumer-facing defect that generates complaints, triggers Amazon listing suspensions, and invites FDA scrutiny.

Structure/Function Claims on the Front Panel

Structure/function claims on the PDP — phrases like "supports immune health" or "promotes restful sleep" — must meet the substantiation standard under 21 CFR Part 101.93 and must be accompanied by the required disclaimer: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." The disclaimer must appear on the label with a specific type size, placement, and formatting. For gummy products sold in small-format packaging where label real estate is limited, meeting the disclaimer requirements while maintaining a clean front panel design is a frequent source of compliance errors.

Allergen Disclosure and Gummy-Specific Ingredient Risks

The Food Allergen Labeling and Consumer Protection Act (FALCPA) requires that the presence of any of the nine major food allergens — milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, soybeans, and sesame — be disclosed on the label either within the ingredient list or in a separate "Contains" statement. Gummy products introduce several allergen vectors that capsule and tablet manufacturers do not typically encounter.

Gelatin sourced from pork or beef is not a major allergen under FALCPA, but fish-derived gelatin — used in some kosher or halal formulations — triggers the fish allergen declaration. Manufacturers who switch gelatin suppliers without updating their allergen review are creating an undisclosed allergen risk. Similarly, some coating agents and natural flavors used in gummy production contain tree nut-derived compounds or dairy derivatives that must be disclosed. Your allergen control program must extend to every raw material in the gummy formula, including processing aids and release agents used in mogul systems or on depositing equipment.

Cross-contact risk from shared equipment is also a labeling consideration. If your facility processes products containing peanuts or tree nuts on the same line as a gummy product that does not declare those allergens, you may need an advisory statement — "Manufactured in a facility that also processes peanuts" — to protect consumers with allergies. Shared equipment allergen risk should be evaluated during your label review process and documented in your allergen control plan as required under 21 CFR Part 111.

Label Review, Version Control, and Change Management

A compliant label at product launch can become a non-compliant label within a single production cycle if formula changes, supplier changes, or serving size adjustments are not captured in the label update process. For gummy manufacturers, the most common trigger for label non-compliance after launch is a formulation change that is not routed through a formal change control review.

Common examples include switching from gelatin to pectin for a vegan line extension without updating the ingredient list, adjusting overage levels after a stability study without recalculating the Supplement Facts panel, or changing a colorant supplier whose product contains a different certified color requiring a different label declaration. Each of these changes requires a label review before the updated formula goes into production. Your change control SOP should explicitly require that any change to a raw material, formula target, or processing parameter triggers a label impact assessment before implementation.

Version control for label files must be maintained with the same rigor you apply to master manufacturing records. Your approved label artwork — with version number, approval date, and signature — should be stored in your quality system and linked to the batch records for every production lot manufactured under that label version. When FDA investigators ask to see your label history, they are looking for exactly this kind of documentation. The inability to produce an approved label version linked to a batch record is a 21 CFR Part 111 documentation deficiency that will appear on a Form 483.

Pre-Launch Label Review Checklist for Gummy Manufacturers

• Supplement Facts panel verified against finished product certificate of analysis and stability data
• Serving size confirmed against validated unit weight range from process validation
• Net quantity of contents confirmed against fill target and count verification data
• Other ingredients list reviewed for accuracy, descending weight order, and allergen status of each component
• Allergen declarations verified against allergen assessment for all raw materials and shared equipment
• Structure/function claims reviewed for substantiation and disclaimer compliance
• Statement of identity present and prominent on PDP
• Color additive declarations verified against supplier documentation
• Label version number assigned, artwork approved, and filed in quality system

Building this checklist into your standard operating procedure for new product launches and label revisions is not optional — it is the documented evidence that your label compliance program is functioning as required under 21 CFR Part 111.70(e) and Part 101. Gummy manufacturers who treat label review as a one-time event at product launch, rather than an ongoing quality system function, are the ones who receive warning letters citing label inaccuracies that could have been caught with a documented review process.